

92. Robert Hightower, Crystal, Minnesota, Court of Federal Claims No: 24–0137V
93. Handson Bota, Boston, Massachusetts, Court of Federal Claims No: 24–0138V
94. Jason Manus, Teterboro, New Jersey, Court of Federal Claims No: 24–0140V
95. Alice Keenan, Holland, Pennsylvania, Court of Federal Claims No: 24–0141V
96. Karina A. Then, Providence, Rhode Island, Court of Federal Claims No: 24–0142V
97. Valerie Parker, Columbus, Ohio, Court of Federal Claims No: 24–0143V
98. Kristen McLaughlin, Universal City, California, Court of Federal Claims No: 24–0147V
99. Jaquel E. Simmons, Waupun, Wisconsin, Court of Federal Claims No: 24–0148V
100. Melissa French, Covington, Kentucky, Court of Federal Claims No: 24–0149V
101. Lisa Regina Vandenberg, Elmwood Park, New Jersey, Court of Federal Claims No: 24–0150V
102. Briana N. Gonzalez on behalf of L. G., Deceased, Aventura, Florida, Court of Federal Claims No: 24–0153V
103. Andrea Flynn, Chapel Hill, North Carolina, Court of Federal Claims No: 24–0154V
104. Stephanie Allstead, Elk Grove, California, Court of Federal Claims No: 24–0156V
105. Debbie Loyim, New York, New York, Court of Federal Claims No: 24–0158V
106. Christina Moser, Woodbridge, Virginia, Court of Federal Claims No: 24–0159V
107. Destiny Ramos on behalf of Y. G. G., Deceased, New York, New York, Court of Federal Claims No: 24–0161V
108. Jamie Mize on behalf of R. P., Deceased, Oakland, California, Court of Federal Claims No: 24–0163V

[FR Doc. 2024–04140 Filed 2–27–24; 8:45 am]

BILLING CODE 4165–15–P

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Stakeholder Listening Session on Public Health Emergencies Preparedness and Response Negotiations

**AGENCY:** Office of Global Affairs, Department of Health and Human Services.

**ACTION:** Notice of public listening session; request for comments.

**DATES:** The listening session will be held Thursday, April 11, 2024, from 10:00 a.m. to 12:00 p.m. Eastern Daylight Time. This session is open to the public but requires RSVP to [oga.rsvp@hhs.gov](mailto:oga.rsvp@hhs.gov) by Friday, April 5, 2024. See *RSVP section in SUPPLEMENTARY INFORMATION* for details.

**ADDRESSES:** The session will be held virtually, with online and dial-in information shared with registered participants.

#### SUPPLEMENTARY INFORMATION:

*Purpose:* The U.S. Department of Health and Human Services (HHS), with support from relevant health-related U.S. Government offices, is charged with leading U.S. participation in the Working Group on the Amendments to the International Health Regulations (2005) (WGIHR) and with co-leading the U.S. delegation to the Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement or other international instrument on pandemic prevention, preparedness and response (INB). HHS will convene an informal Stakeholder Listening Session.

The Stakeholder Listening Session is designed to seek input from stakeholders and subject matter experts to help inform U.S. Government engagement with the WGIHR and INB.

*Background, WGIHR:* The World Health Assembly originally adopted the International Health Regulations (IHR) in 1969. The regulations were amended multiple times, most recently in 2005. The purpose of IHR is to prevent, protect against, control, and provide public health response to the international spread of disease.

Member States of the World Health Organization (WHO) agreed in 2022 to embark on a process to amend the current IHR. The process builds on lessons learned from the various review panels that examined the functioning of the IHR and the global health security architecture during the COVID–19 pandemic. The Working Group on the Amendments to the IHR (WGIHR) is considering more than 300 proposed amendments to 33 of the 66 articles of the IHR and 5 of its 9 annexes, plus 6 new articles and 2 new annexes. More information on the WGIHR can be found here: <https://www.who.int/teams/ihr/working-group-on-amendments-to-the-international-health-regulations-%282005%29>.

The WGIHR currently intends to submit its outcome to the Seventy-seventh World Health Assembly in May 2024.

*Background, INB:* In December 2021, WHO Member States decided at a Special Session of the World Health Assembly to establish an intergovernmental negotiating body (INB), representing all regions of the world, to draft and negotiate a WHO convention, agreement, or other international instrument on pandemic prevention, preparedness, and response. More information about the INB process can be found here: <https://inb.who.int/home/inb-process>.

The INB currently intends to submit its outcome to the Seventy-seventh World Health Assembly in May 2024.

The United States has expressed support for the development of an international instrument to protect the world from pandemic health threats now and in the future, and in a more rapid and equitable manner.

The United States is seeking the following key outcomes in the negotiations:

- Enhance the capacity of countries around the world to prevent, prepare for, and respond to pandemic emergencies and provide clear, credible, consistent information to their citizens.
- Ensure that all countries share data and laboratory samples from emerging outbreaks quickly, safely, and transparently to facilitate response efforts and inform public health decision making regarding effective disease control measures, including the rapid creation of safe and effective vaccines, diagnostic tests, and treatments.

- Support more equitable and timely access to, and delivery of, vaccines, diagnostic tests, treatments, and other mitigation measures to quickly contain outbreaks, reduce illness and death, and minimize impacts on the economic and national security of people around the world.

*Matters to be Discussed:* The listening session will discuss the outcome products of the WGIHR and INB to be submitted to the Seventy-seventh World Health Assembly in May. Topics will include those amendments currently under consideration by the WGIHR; areas of consideration included in the Pandemic Accord; and key proposals that highlight the intersection between the IHR and the Pandemic Accord. An Article-by-Article Compilation of Proposed Amendments to the International Health Regulations (2005) can be found here: [https://apps.who.int/gb/wgihrr/pdf\\_files/wgihrr1/WGIHR\\_Compilation-en.pdf](https://apps.who.int/gb/wgihrr/pdf_files/wgihrr1/WGIHR_Compilation-en.pdf). More information on the Pandemic Accord can be found here: <https://apps.who.int/gb/inb/index.html>.

Participation is welcome from stakeholder communities, including:

- Public health and advocacy groups
- State, local, and Tribal groups
- Private industry
- Minority health organizations
- Academic and scientific organizations, etc.

*RSVP:* Persons seeking to participate in the listening session *must register by Friday, April 5, 2024*.

*Registrants must include their full name, email address, and organization, if any, and indicate whether they are registering as a listen-only attendee or as a speaker participant to [oga.rsvp@hhs.gov](mailto:oga.rsvp@hhs.gov).*

Requests to participate as a speaker must include all of the following information:

1. The name and email address of the person desiring to participate
2. The organization(s) that person represents, if any
3. The document(s) and primary article(s) of interest, listed in order of the speaker's priorities

*Other Information:* Written comments should be emailed to [oga.rsvp@hhs.gov](mailto:oga.rsvp@hhs.gov) with the subject line "Written Comment Re: Stakeholder Listening Session on public health emergencies preparedness and response negotiations" by Wednesday, April 17, 2024.

We look forward to your comments on these matters.

Dated: February 22, 2024.

**Susan Kim,**

*Principal Deputy Assistant Secretary.*

[FR Doc. 2024-04080 Filed 2-27-24; 8:45 am]

**BILLING CODE 4150-38-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### Government-Owned Inventions; Availability for Licensing

**AGENCY:** National Institutes of Health, HHS.

**ACTION:** Notice.

**SUMMARY:** The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

**FOR FURTHER INFORMATION CONTACT:** Wade Green at (301) 761-7505 or [greenww@nih.gov](mailto:greenww@nih.gov). Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention.

**SUPPLEMENTARY INFORMATION:** Technology description follows:

An Innovative Adapter for Expedited and Automated Thawing of viably Frozen Cells.

### Description of Technology

This technology is a device and system for expediting the thawing frozen specimens (e.g., cryopreserved cells) contained in cryo-vials, offering a breakthrough solution for researchers seeking efficiency and precision in their workflows. The device is equipped with a small elongated tubular adaptor that suspends a cryo-vial of frozen cells over a centrifuge tube containing culture medium in an inverted position. With a focus on speed, efficiency and automation, the adaptor dramatically expedites the process of recovering viable cells from frozen specimens. It reduces per-sample labor time for thawing from several minutes to a few seconds, enabling a single technician to simultaneously thaw multiple vials within the capacity of centrifuges. The cells, once thawed, are diluted instantly into growth medium contained in the centrifuge tubes and spend essentially no time in liquid cryopreservative.

The automated mechanism ensures a precise and controlled thawing environment maintaining optimal temperature conditions throughout the thawing process.

#### *Potential Commercial Applications:*

- This device can be used in sample preparation and cell culturing.
- Applicable for research materials, medical and non-medical devices and consumer products.

#### *Competitive Advantages:*

- Provides a faster process of recovering viable cells from frozen specimens.
- Eliminates multi-step processes.
- High throughput system with reduced variability.
- Constant environment control.

#### *Development Stage:*

- Prototype

*Inventors:* Dr. Mario Roederer, Dr. Pratip Chattopadhyay and Margaret Beddall, all of NIAID.

*Publications:* n/a.

*Intellectual Property:* HHS Reference No. E-080-2015-0-EIR-00 U.S. Patent Application No. 14/661,449, filed on March 18, 2015; Published Patent Application US20160274004A1 on September 22, 2016; U.S. Patent 9,663,812 issued May 30, 2017.

*Licensing Contact:* To license this technology, please contact Wade Green at (301) 761-7505 or [greenww@nih.gov](mailto:greenww@nih.gov) and reference E-080-2015.

*Collaborative Research Opportunity:* The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For

collaboration opportunities, please contact Wade Green at (301) 761-7505 or [greenww@nih.gov](mailto:greenww@nih.gov).

Dated: February 7, 2024.

**Surekha Vathyam,**

*Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.*

[FR Doc. 2024-04060 Filed 2-27-24; 8:45 am]

**BILLING CODE 4140-01-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Institute of Environmental Health Sciences; Notice of Closed Meetings

Pursuant to section 1009 of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Institute of Environmental Health Sciences Special Emphasis Panel; Career Development in K Applications.

*Date:* March 20-21, 2024.

*Time:* 10:00 a.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institute of Environmental Health Science, 530 Davis Drive, Keystone Building, Durham, NC 27713 (Virtual Meeting).

*Contact Person:* Beverly W. Duncan, Ph.D., Scientific Review Officer, Division of Extramural Research and Training, National Institute of Environmental Health Science, Keystone Building, 530 Davis Drive, Room 3130, Durham, NC 27713. (240) 353-6598, [beverly.duncan@nih.gov](mailto:beverly.duncan@nih.gov).

*Name of Committee:* National Institute of Environmental Health Sciences Special Emphasis Panel; Exposome Research Coordination to Accelerate Precision Environmental Health (PEH).

*Date:* April 3, 2024.

*Time:* 10:30 a.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Institute of Environmental Health Science, 530 Davis Drive, Keystone Building, Durham, NC 27713 (Virtual Meeting).

*Contact Person:* Leroy Worth, Ph.D., Scientific Review Officer, Scientific Review